Condition
Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma
Estimated Enrollment: 16
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 2007LS086|0712M22703
Study First Received: June 20, 2008
Last Updated: November 6, 2012
Estimated Primary Completion Date: September 2010
Primary Outcome Measures:
Maximum tolerated dose of sorafenib tosylate|Disease Response|Maximum, Minimum and AUC Concentrations of Sorafenib
Sponsors and Collaborators:
Masonic Cancer Center, University of Minnesota
Website Link: https://ClinicalTrials.gov/show/NCT00703638
